Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
26,288,053
-
Total 13F shares
-
10,799,701
-
Share change
-
+2,314,808
-
Total reported value
-
$12,545,188
-
Price per share
-
$1.16
-
Number of holders
-
46
-
Value change
-
+$2,685,239
-
Number of buys
-
25
-
Number of sells
-
9
Institutional Holders of Rein Therapeutics, Inc. - Common Stock, $0.001 par value (RNTX) as of Q4 2025
As of 31 Dec 2025,
Rein Therapeutics, Inc. - Common Stock, $0.001 par value (RNTX) was held by
46 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
10,799,701 shares.
The largest 10 holders included
Voss Capital, LP, BIOS Capital Management, LP, VANGUARD GROUP INC, UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO, Prosight Management, LP, Cable Car Capital, LP, GEODE CAPITAL MANAGEMENT, LLC, Texas Capital Bank Wealth Management Services Inc, Sigma Planning Corp, and GAGNON SECURITIES LLC.
This page lists
46
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.